Robin Roberts, COO and co-founder of the Novartis Biome, was on site at JP Morgan last month in San Francisco, but we weren’t able to pin him down for an interview.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh